The clinical effects of an intravenous perioperative lidocaine infusion during hepatectomy: a pilot study.
5 affiliations
- 1Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- 2Association for Research in Anaesthesia and Intensive Care (ACATI), Cluj-Napoca, Romania.
- 3Regional Institute of Gastroenterology & Hepatology, Cluj-Napoca, Romania.
- 4Romania Onco-Anaesthesia Research Group, ESAIC, Brussels, Belgium.
- 5Outcome Research Consortium, Cleveland, Ohio, USA.
Abstract
Intravenous (i.v.) lidocaine exhibits multimodal analgesic, anti-inflammatory, and anticancer properties. However, concerns regarding systemic toxicity and impaired hepatic drug clearance during liver resection necessitate caution in perioperative dosing protocols. This study aimed to evaluate the clinical recovery parameters and systemic inflammatory markers following continuous perioperative i.v. lidocaine infusion in patients undergoing elective hepatectomy for hepatocellular carcinoma (HCC). In this prospective, randomized controlled trial, 60 patients undergoing elective surgical resection for HCC were assigned (1:1 ratio) to either a lidocaine group (n=30) or a control group (n=30). The lidocaine group received an intraoperative IV bolus (1.5 mg/kg) followed by a continuous infusion (1 mg/kg/h), maintained throughout surgery and for 24 hours postoperatively. Primary endpoints evaluated 24 hour opioid consumption, Numeric Rating Scale pain scores, return of bowel function, length of hospital stay, and perioperative inflammatory response. No statistically significant differences were observed between the lidocaine and control groups across clinical recovery outcomes. Intraoperative fentanyl consumption was identical between groups 0.8±0.1 mg (vs. 0.8±0.2 mg; p=0.957). The lidocaine group demonstrated a non-significant trends toward reduced 24-hour postoperative morphine consumption (13.5±13.3 mg vs. 19.5±15.8 mg; p=0.224), lower mean 24-hour NRS pain scores (3.36±1.77 vs. 3.80±1.85; p=0.275), and faster recovery of bowel motility (3.0±0.9 vs. 3.4±1.5 days; p=0.215). Length of hospital stay was comparable (9.46±3.15 vs. 8.47±3.09 days; p=0.340). Both groups exhibited significant postoperative increases in CRP and leukocyte levels (p<0.05), with no significant between-group differences postoperatively. A modified, lower-dose perioperative i.v. lidocaine regimen tailored for toxicity safety in patients with liver resection is well-tolerated but does not yield statistically significant reductions in postoperative opioid consumption, pain scores, bowel recovery time, systemic inflammatory markers, or hospital stay following open hepatectomy. Further, adequately powered studies are needed.
Related
- Clinical Outcomes and Inflammatory Biomarker Changes After Intravenous Ketamine-Lidocaine Infusion in Refractory Neuropathic Pain: A Prospective Observational Pilot Study.
- Perioperative intravenous lidocaine for the prevention of chronic postsurgical pain: a systematic review and meta-analysis of randomized controlled trials
- Perioperative Intravenous Antibiotic Regimens and Surgical Site Infection After Colorectal Surgery: Clinical Associations and External Evaluation of Risk Prediction Models
- Intraoperative intravenous lidocaine for analgesia after oral cancer surgery with free perforator flap reconstruction: a randomised controlled trial
- Development and external validation of an explainable machine learning model using routine perioperative clinical variables for postoperative pulmonary complication risk stratification after hepatectomy for primary liver cancer.
BibTeX
@article{sargarovschi2026clinical,
title = {{The clinical effects of an intravenous perioperative lidocaine infusion during hepatectomy: a pilot study.}},
author = {Sergiu Sargarovschi and Andreea Abouritei and Ioana Rucsanda and Dan Valean and Raluca M Hategan and Daniela Ionescu},
journal = {Medicine and pharmacy reports},
year = {2026},
month = oct,
doi = {10.15386/mpr-3015},
url = {https://europepmc.org/article/MED/42997649},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - The clinical effects of an intravenous perioperative lidocaine infusion during hepatectomy: a pilot study.
AU - Sergiu Sargarovschi
AU - Andreea Abouritei
AU - Ioana Rucsanda
AU - Dan Valean
AU - Raluca M Hategan
AU - Daniela Ionescu
PY - 2026
DA - 2026/10/31
JO - Medicine and pharmacy reports
DO - 10.15386/mpr-3015
UR - https://europepmc.org/article/MED/42997649
AB - Intravenous (i.v.) lidocaine exhibits multimodal analgesic, anti-inflammatory, and anticancer properties. However, concerns regarding systemic toxicity and impaired hepatic drug clearance during liver resection necessitate caution in perioperative dosing protocols. This study aimed to evaluate the clinical recovery parameters and systemic inflammatory markers following continuous perioperative i.v. lidocaine infusion in patients undergoing elective hepatectomy for hepatocellular carcinoma (HCC). In this prospective, randomized controlled trial, 60 patients undergoing elective surgical resection for HCC were assigned (1:1 ratio) to either a lidocaine group (n=30) or a control group (n=30). The lidocaine group received an intraoperative IV bolus (1.5 mg/kg) followed by a continuous infusion (1 mg/kg/h), maintained throughout surgery and for 24 hours postoperatively. Primary endpoints evaluated 24 hour opioid consumption, Numeric Rating Scale pain scores, return of bowel function, length of hospital stay, and perioperative inflammatory response. No statistically significant differences were observed between the lidocaine and control groups across clinical recovery outcomes. Intraoperative fentanyl consumption was identical between groups 0.8±0.1 mg (vs. 0.8±0.2 mg; p=0.957). The lidocaine group demonstrated a non-significant trends toward reduced 24-hour postoperative morphine consumption (13.5±13.3 mg vs. 19.5±15.8 mg; p=0.224), lower mean 24-hour NRS pain scores (3.36±1.77 vs. 3.80±1.85; p=0.275), and faster recovery of bowel motility (3.0±0.9 vs. 3.4±1.5 days; p=0.215). Length of hospital stay was comparable (9.46±3.15 vs. 8.47±3.09 days; p=0.340). Both groups exhibited significant postoperative increases in CRP and leukocyte levels (p<0.05), with no significant between-group differences postoperatively. A modified, lower-dose perioperative i.v. lidocaine regimen tailored for toxicity safety in patients with liver resection is well-tolerated but does not yield statistically significant reductions in postoperative opioid consumption, pain scores, bowel recovery time, systemic inflammatory markers, or hospital stay following open hepatectomy. Further, adequately powered studies are needed.
SN - 2602-0807
SN - 2668-0572
ER -